Novavax Trivalent Influenza VLP Vaccine

Novavax Trivalent Influenza VLP Vaccine is a recombinant vaccine candidate developed for the prevention of seasonal influenza. It utilizes virus-like particle (VLP) technology, where the vaccine particles mimic the external structure of the influenza virus—including the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins—but lack the internal genetic material required for viral replication. These VLPs are produced using a recombinant baculovirus expression system in Sf9 insect cells. The trivalent formulation was designed to provide protection against three seasonal influenza strains, typically two Influenza A subtypes (H1N1 and H3N2) and one Influenza B lineage. In Phase 2 clinical trials, the vaccine was evaluated at doses of 15 µg and 60 µg per strain in older adults, demonstrating safety and the ability to induce hemagglutination inhibition (HAI) antibody titers comparable to licensed trivalent inactivated vaccines.

Other names

trivalent inactivated influenza vaccine-Novavax-InfluenzaTrivalent Seasonal Influenza Virus-Like Particle VaccineRecombinant Influenza VLP VaccineInfluenza VLP Vaccine (Recombinant)